These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

346 related items for PubMed ID: 20215482

  • 1. Acute cholecystitis in a patient with metastatic renal cell carcinoma treated with everolimus.
    Cetin B, Coskun U, Yildiz R, Buyukberber S, Baykara M, Benekli M.
    J Oncol Pharm Pract; 2011 Sep; 17(3):274-8. PubMed ID: 20215482
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R, Boni JP, Ravaud A.
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [Abstract] [Full Text] [Related]

  • 4. Third-line sorafenib after sequential therapy with sunitinib and mTOR inhibitors in metastatic renal cell carcinoma.
    Di Lorenzo G, Buonerba C, Federico P, Rescigno P, Milella M, Ortega C, Aieta M, D'Aniello C, Longo N, Felici A, Ruggeri EM, Palmieri G, Imbimbo C, Aglietta M, De Placido S, Mirone V.
    Eur Urol; 2010 Dec; 58(6):906-11. PubMed ID: 20884115
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Everolimus in renal cell carcinoma.
    Wang Y.
    Drugs Today (Barc); 2010 Aug; 46(8):557-66. PubMed ID: 20830316
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
    Chan HY, Grossman AB, Bukowski RM.
    Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer.
    Amato RJ, Jac J, Giessinger S, Saxena S, Willis JP.
    Cancer; 2009 Jun 01; 115(11):2438-46. PubMed ID: 19306412
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Are tyrosine kinase inhibitors still active in patients with metastatic renal cell carcinoma previously treated with a tyrosine kinase inhibitor and everolimus? Experience of 36 patients treated in France in the RECORD-1 Trial.
    Blesius A, Beuselinck B, Chevreau C, Ravaud A, Rolland F, Oudard S, Escudier B.
    Clin Genitourin Cancer; 2013 Jun 01; 11(2):128-33. PubMed ID: 23332872
    [Abstract] [Full Text] [Related]

  • 15. Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 Mutation.
    Ali SM, Stephens PJ, Miller VA, Ross JS, Pal SK.
    Eur Urol; 2015 Aug 01; 68(2):341-3. PubMed ID: 25796537
    [No Abstract] [Full Text] [Related]

  • 16. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma.
    Harzstark AL, Small EJ, Weinberg VK, Sun J, Ryan CJ, Lin AM, Fong L, Brocks DR, Rosenberg JE.
    Cancer; 2011 Sep 15; 117(18):4194-200. PubMed ID: 21387258
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.